Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5605733 | 1.00 | IDO1 (0.33) | IDO1TDO2MAPT | |
| SCHEMBL14458060 | 0.76 | MAPT (0.36) | IDO1TDO2MAPT | |
| SCHEMBL14458061 | 0.76 | MAPT (0.36) | IDO1TDO2MAPT | |
| SCHEMBL3158686 | 0.75 | MAPT (0.36) | IDO1TDO2MAPT | |
| SCHEMBL3632209 | 0.75 | MAPT (0.36) | IDO1TDO2MAPT | |
| SCHEMBL3161230 | 0.75 | MAPT (0.36) | IDO1TDO2MAPT | |
| SCHEMBL3659400 | 0.72 | MAPT (0.34) | MAPT | |
| SCHEMBL3659823 | 0.72 | MAPT (0.34) | MAPT | |
| SCHEMBL14279199 | 0.64 | MAPT (0.46) | IDO1TDO2MAPT | |
| SCHEMBL13479444 | 0.64 | MAPT (0.46) | IDO1TDO2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018114732-A1 | PROCESS FOR PREPARING (4S)- OR (4R)-3,4-DIHYDROXY-2,6,6-TRIMETHYLCYCLOHEX-2-ENONE | BASF SE (DE) | 2018-06-28 | — | — | WO | disclosed |
| EP-2089530-B1 | PROCESS FOR THE PREPARATION OF (4S)-3,4-DIHYDROXY-2,6,6-TRIMETHYL-CYCLOHEX-2-ENONE AND DERIVATIVES THEREOF EMPLOYING THE AZOARCUS PHENYLETHANOL DEHYDROGENASE | BASF SE (DE) | 2010-03-03 | — | — | EP | disclosed |
| US-20100041922-A1 | METHOD FOR THE ENANTIOSELECTIVE PRODUCTION OF OPTICALLY ACTIVE 4-HYDROXY-2,6,6-TRIMETHYL-CYCLOHEX-2-ENONE DERIVATIVES | BASF SE (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041922-A1 | METHOD FOR THE ENANTIOSELECTIVE PRODUCTION OF OPTICALLY ACTIVE 4-HYDROXY-2,6,6-TRIMETHYL-CYCLOHEX-2-ENONE DERIVATIVES | BASF SE (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20090325225-A1 | METHOD FOR THE PRODUCTION OF (4S)-3,4-DIHYDROXY-2,6,6-TRIMETHYL-CYCLOHEX-2-ENONE AND DERIVATIVES THEREOF | BASF AKTIENGESELLSCHAFT PATENTS, TRADEMARKS AND LICENSES (DE) | 2009-12-31 | — | — | US | disclosed |
| EP-2089530-A2 | METHOD FOR THE PRODUCTION OF (4S)-3, 4-DIHYDROXY-2,6, 6-TRIMETHYL-CYCLOHEX-2-ENONE AND DERIVATIVES THEREOF | BASF SE (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008116714-A1 | METHOD FOR THE ENANTIOSELECTIVE PRODUCTION OF OPTICALLY ACTIVE 4-HYDROXY-2,6,6-TRIMETHYL-CYCLOHEX-2-ENONE DERIVATIVES | BASF SE (DE) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008055988-A2 | METHOD FOR THE PRODUCTION OF (4S)-3, 4-DIHYDROXY-2,6, 6-TRIMETHYL-CYCLOHEX-2-ENONE AND DERIVATIVES THEREOF USING AZOARCUS PHENYLETHANOL DEHYDROGENASE | BASF SE (DE) | 2008-05-15 | — | — | WO | disclosed |
| US-7247752-B2 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | CARDAX PHARMACEUTICALS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247752-B2 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | CARDAX PHARMACEUTICALS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247752-B2 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | CARDAX PHARMACEUTICALS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060183947-A1 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | CARDAX PHARMA, INC. | 2006-08-17 | — | — | US | disclosed |
| US-20060183185-A1 | Method for the synthesis of astaxanthin | CARDAX PHARMACEUTICALS, INC. | 2006-08-17 | — | — | US | disclosed |
| US-20060178538-A1 | Methods for the synthesis of chiral dihydroxy intermediates useful for the chiral synthesis of carotenoids | CARDAX PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| US-20060167319-A1 | Methods for the synthesis of unsaturated ketone intermediates useful for the synthesis of carotenoids | CARDAX PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060155150-A1 | Methods for the synthesis of lutein | CARDAX PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| US-20060111580-A1 | Methods for the synthesis of chiral dihydroxy ketone intermediates useful for the chiral synthesis of carotenoids | CARDAX PHARMACEUTICALS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20060088905-A1 | Methods for the synthesis of zeazanthin | CARDAX PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-20060088904-A1 | Methods for the synthesis of astaxanthin | CARDAX PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041922-A1 | METHOD FOR THE ENANTIOSELECTIVE PRODUCTION OF OPTICALLY ACTIVE 4-HYDROXY-2,6,6-TRIMETHYL-CYCLOHEX-2-ENONE DERIVATIVES | CYP8B1, CYP51A1, HSD3B1 | IDO1 724/4885TDO2 183/4885MAPT 4592/4885 |
| US-20060088904-A1 | Methods for the synthesis of astaxanthin | HSD17B7, CYP51A1, HSD11B1 | IDO1 584/4885TDO2 198/4885MAPT 4401/4885 |
| US-20060178538-A1 | Methods for the synthesis of chiral dihydroxy intermediates useful for the chiral synthesis of carotenoids | HSD17B7, DHPS, DHCR7 | IDO1 215/4885TDO2 118/4885MAPT 4658/4885 |
| US-20060167319-A1 | Methods for the synthesis of unsaturated ketone intermediates useful for the synthesis of carotenoids | DHPS, HSD17B7, COASY | IDO1 2416/4885TDO2 1368/4885MAPT 4097/4885 |
| US-20060155150-A1 | Methods for the synthesis of lutein | LSS, DHPS, CYP51A1 | IDO1 758/4885TDO2 251/4885MAPT 4321/4885 |
| US-20060183947-A1 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | DHCR7, HSD17B7, HSD11B1 | IDO1 331/4885TDO2 65/4885MAPT 4806/4885 |
| US-20060088905-A1 | Methods for the synthesis of zeazanthin | DHPS, CYP51A1, HSD17B7 | IDO1 803/4885TDO2 290/4885MAPT 3380/4885 |
| US-20060111580-A1 | Methods for the synthesis of chiral dihydroxy ketone intermediates useful for the chiral synthesis of carotenoids | DHPS, DHCR7, HSD17B7 | IDO1 1265/4885TDO2 332/4885MAPT 4150/4885 |
| US-20060183185-A1 | Method for the synthesis of astaxanthin | SQLE, HSD17B7, CYP51A1 | IDO1 935/4885TDO2 502/4885MAPT 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.